Angiotensin-converting enzyme 2 (ACE2) from raccoon dog can serve as an efficient receptor for the spike protein of severe acute respiratory syndrome coronavirus

Lili Xu,1 Yanfang Zhang,1 Yun Liu,1 Zhiwei Chen,2 Hongkui Deng,3 Zhongbin Ma,1 Hualin Wang,1 Zhihong Hu1 and Fei Deng1

1State Key Laboratory of Virology, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan 430071, PR China
2AIDS Institute, The University of Hong Kong Li Ka Shing Faculty of Medicine, Hong Kong SAR
3Department of Cell Biology and Genetics, College of Life Sciences, Peking University, Beijing 100871, PR China

Received 20 May 2009
Accepted 19 July 2009

INTRODUCTION
Severe acute respiratory syndrome (SARS), a disease that first occurred in November 2002 in Guangdong Province, China, has caused over 8000 infections worldwide with a fatality rate up to 10% within several months (WHO, 2004). A novel coronavirus, SARS-CoV, was identified as the aetiological agent of the disease (Drosten et al., 2003; Fouchier et al., 2003; Ksiazek et al., 2003; Peiris et al., 2003) and phylogenetic analysis indicated that the virus was different from previously known coronaviruses (Marra et al., 2003; Rota et al., 2003).

Although the identification of the aetiological agent and molecular studies on SARS-CoV proceeded rather rapidly, the puzzle of the origin of the disease was still not fully resolved. There appears to be a reservoir for SARS-CoV in wild animals, because a high proportion of early SARS patients were food handlers with likely animal contact in Guangdong Province (Normile & Enserink, 2003). SARS-CoV-like viruses with extremely high sequence identity to SARS-CoV were isolated from masked palm civets (Paguma larvata) and a raccoon dog (Nyctereutes procyonoides) from a live-animal market, suggesting that these animals played important roles in the transmission of SARS-CoV (Guan et al., 2003). Later on, several investigations confirmed that masked palm civet in the market was a critical intermediate host, but not a natural reservoir, for SARS-CoV (Tu et al., 2004; Kan et al., 2005; Poon et al., 2005; Song et al., 2005; Wang et al., 2005). Horseshoe bat was later on identified as a natural reservoir for SARS-CoV-like viruses (Lau et al., 2005; W. Li et al., 2005b); however, the variation of the spike (S) protein of bat SARS-CoV-like virus indicated that the viruses discovered so far from bats cannot infect human cells directly (Ren et al.,...
SARS-CoV uses a cell-surface zinc peptidase, angiotensin-converting enzyme 2 (ACE2), as its receptor (Li et al., 2003). ACE2 genes from several species have been sequenced and it has been shown that the efficiencies of infection in humans, mice and rats correlate with the ability of the ACE2 from each species to support virus replication (Li et al., 2004; Subbarao et al., 2004; Wentworth et al., 2004).

Although SARS-CoV-like viruses were detected from raccoon dogs in both 2003 and 2004 (Guan et al., 2003; Kan et al., 2005), very limited research was focused on the role of raccoon dogs in the SARS epidemic. In this study, ACE2 was extracted from raccoon dog, and a HeLa cell line stably expressing the raccoon dog ACE2 (rdACE2) protein was established. By using pseudotyped SARS-CoV, we determined whether rdACE2 can be used as the receptor for SARS-CoV and its efficiency in comparison to ACE2 proteins from human and masked palm civet. We hope that the results further our understanding of the role of the raccoon dog in the SARS epidemic, and provide useful data for prevention of the possible re-emergence of SARS.

METHODS

RNA extraction, DNA sequencing and analysis. RNA was extracted from a mixture of the heart, liver, spleen and lung from a raccoon dog (obtained in October 2006 from a live-animal retail market in Hebei Province, China) with TRIzol (Invitrogen), according to the manufacturer’s instructions. RNA was dissolved in 20 µl diethyl pyrocarboxate-treated water and stored at −80 °C.

RNA was reverse-transcribed to cDNA by using a combined gene-specific priming, random-priming and oligo-dT-priming strategy by using SuperScript II reverse transcriptase (Invitrogen). Overlapping DNA fragments covering the full-length ACE2 gene were produced by PCR using the following primers, which were designed based on the most conserved regions of a sequence alignment of ACE2 genes from ten SARS-associated animals: ACE2F1, 5'- CCGGATCCATGTCAGGCTCTTCCTGGCTC-3'; ACE2F2, 5'- GGATCCATGGCCATCACTTCTTTGTCAC-3'; ACE2F3, 5'- CCGGGTATTGGACAAACGATTGACAC-3'; ACE2F4, 5'- CCGGGATCGCTGATATTGGACAAATCTGT-3'; ACE2F5, 5'- CCGGGATCGCTGATATTGGACAAATCTGT-3'; ACE2R1, 5'- CTTTTTGGACAAATCTGT-3'; ACE2F5, 5'- CCGGGATCGCTGATATTGGACAAATCTGT-3'; ACE2R2, 5'- GGCTGAGACAAAGCTTTTTCGACTCTC-3'; ACE2R3, 5'- GGCTGAGACAAAGCTTTTTCGACTCTC-3'; ACE2R4, 5'- GGCTGAGACAAAGCTTTTTCGACTCTC-3'; ACE2R5, 5'- GGCTGAGACAAAGCTTTTTCGACTCTC-3'. The underlined sequences are restriction-enzyme digestion sites.

The PCR products were cloned into the pGEM-T Easy vector (Promega) separately for sequencing, which was performed on a CEQ8000 sequencer (Beckman Coulter) with M13 forward and reverse primers (M13F, 5'- GGCTGAGACAAAGCTTTTTCGACTCTC-3'; M13R, 5'- TCACAGGAAACGACTATGAC-3'). Then, all five PCR fragments were spliced by the overlap-extension PCR method (Horton et al., 1989) to obtain the full-length rdACE2 gene, which was sequenced again for absolute accuracy of the rdACE2 sequence.

Alignment analyses of nucleic acid and amino acid sequences were performed by using the CLUSTAL W (version 1.83) software (Thompson et al., 1994). Phylogenetic trees were constructed based on amino acid sequences by using the neighbour-joining algorithm in the MEGA3.1 software package (Kumar et al., 2004).

Generation of cell lines stably expressing ACE2 proteins. The HeLa-huACE2 and HeLa-pcACE2 cell lines, which stably express ACE2 from human and palm civet, respectively, were constructed previously (Qu et al., 2005). Generation of a cell line stably expressing rdACE2 was established by using a Moloney murine leukemia virus-based pseudotyped system termed pVPack (Stratagene). Briefly, the rdACE2 gene was cloned into retroviral vector pFB-Neo to generate pFB-rdACE2, then HEK293T cells were cotransfected by the calcium phosphate method with pFB-rdACE2, a vesicular stomatitis virus protein G (VSV-G)-expressing vector (pVPack-VSV-G) and a gag-pol-expressing vector (pVPack-GP). At 48 h post-transfection, viral supernatants were harvested, cell debris was cleared by centrifugation and HeLa cells were then transduced. The medium was replaced 8 h post-transduction and the cells were selected in growth medium containing 800 µg/ml G418 (Amresco). A cell line stably expressing rdACE2 was selected by limiting dilution for four passages in 1 month.

Rabbit polyclonal antibodies against huACE2, pcACE2 and rdACE2 were generated with recombinant full-length ACE2 proteins expressed in the pProEXHT (Gibco-BRL) expression system. Purified proteins (200 µg) were used to immunize rabbits. After 3 weeks, the rabbits received a booster with the same amount of the antigens. Two weeks later, antisera were collected and stored at −80 °C.

Stable expression of human, palm civet and raccoon dog ACE2 in HeLa cells was detected by using rabbit antibodies against huACE2, pcACE2 and rdACE2, respectively. Also, cross-reactions between ACE2 proteins and anti-ACE2 antibodies were tested. Cell lysates were separated by SDS-PAGE and then transferred to nitrocellulose membranes (Millipore). The membranes were incubated separately with rabbit anti-huACE2, anti-pcACE2 and anti-rdACE2 (1:1000) and bound antibodies were detected by using alkaline phosphatase-conjugated goat anti-rabbit IgG (1:2000) (SABC). The signal was detected with a BCIP-nitro blue tetrazolium kit (SABC).

Fluorescence-activated cell sorting (FACS) analysis of ACE2-expressing cells. Firstly, rabbit anti-huACE2 antibody was purified by protein A-Sepharose chromatography (Calbiochem) and conjugated with fluorescein isothiocyanate (FITC; AnaSpec) in DMSO (Sigma). Secondly, ACE2-expressing and control HeLa cells were cultured on coverslips in 24-well plates (Corning). The following day, the cells were washed with cold PBS and harvested with PBS containing 5 mM EDTA for 10 min at 4 °C and spun at 1000 g for 5 min, followed by overnight incubation with FITC-conjugated rabbit anti-huACE2 antibody (at a 1:100 dilution in PBS with 3% goat serum) at 4 °C. The next day, after two washes with cold PBS, the cells were fixed by resuspending them in 2% paraformaldehyde and incubated at room temperature for 15 min. Finally, the cells were washed twice and resuspended in 500 µl cold PBS, and flow-cytometry analysis (Epics Altra II; Beckman Coulter) was performed.

ACE2 activity assay. The cell-membrane fraction was prepared by using a ProteoPrep Membrane Extraction kit (Sigma). The protein content of the membrane was determined with a BCA Protein Assay Kit (Biyotime), using bovine serum albumin as a standard. The activity of the ACE2 assay was determined as described by Douglas et al. (2004) using the ACE2-specific quenched fluorescent substrate QFS (-7-methoxycoumarin-4-yl)-acetyl-Ala-Pro-Lys(2,4-dinitrophenyl) (Auspep). Assays were performed in black 96-well plates with 50 µM QFS per reaction and incubated at 37 °C for 1 h. Liberated fluorescence (in relative fluorescence units) was measured at 480 nm.
320–420 nm. To demonstrate specific inhibition, ACE2 activity was also determined in the presence of 0.1 mM EDTA.

**Construction of full-length S genes with distinct receptor-binding domain (RBD) sequences.** Four full-length SARS-CoV S genes with a codon-optimized S backbone from human SARS-CoV, but with distinct RBD sequences from strain BJ01 (human), palm civets in Guangdong Province (pcGD) and in Hubei Province (pcES) and a raccoon dog in Shenzhen from 2003 (rd03SZ), were generated in a previous study (Liu et al., 2007). For the current study, the RBD sequence of the S gene from a raccoon dog in Guangzhou from 2004 (rd04GZ) was constructed by site-directed mutagenesis. Primers were designed based on the sequences of S genes A030 (GenBank accession no. AY687357) and A031 (accession no. AY687358), which were detected in market raccoon dogs in 2004 and have 100% sequence identity. All five S genes were cloned individually into the pcDNA3.1 backbone (30 m).

**Virus entry assay with HIV-luc/SARS-pseudotyped virus.** The pseudoviruses were generated by cotransfecting 5 × 10⁶ HEK293T cells in 100 mm cell-culture dishes (Corning) with a human immunodeficiency virus type 1 (HIV-1) pNL4.3Luc env Vpr backbone (30 m) and one of the above-mentioned, full-length S gene-expression plasmids (30 m) by using Lipofectamine 2000 (Invitrogen). Viral supernatants were harvested 48 h post-transfection, clarified from cell debris by centrifugation at 3000 g for 10 min and filtered through a 0.45 μm pore-size filter (Millipore).

**Sequence analysis of the rdACE2 protein.** The full-length sequence of raccoon dog ACE2 was obtained by cloning and sequencing as described in Methods. The coding region was deposited in GenBank under accession number EU024940.

The rdACE2 gene encodes an 804 aa protein, which is identical in size to the ACE2 protein of dog, but 1 aa shorter than those of human and palm civet. Sequence alignment indicated that the rdACE2 molecule has an amino acid sequence identity of 99.3% to dog ACE2, 90.7% to cat ACE2, 90.5% to raccoon ACE2, 89.2% to pcACE2, 83.9% to huACE2, 81.6% to mouse ACE2, 81.4% to rat ACE2, 80.5% to ferret ACE2 and 80.4% to bat ACE2. ACE2 of raccoon dog was almost identical to dog ACE2, with only six amino acid differences at residues 26, 52, 59, 326, 340 and 353. A sequence alignment and a phylogenetic tree shown in Fig. 1. There appear to be four groups of ACE2 proteins based on phylogenetic analysis: group I contains the ACE2 proteins of raccoon dog, dog, ferret, raccoon, masked palm civet and cat, group II contains those of human and VeroE6 cells, group III contains those of mouse and rat and group IV contains that of bat (Fig. 1b).

It was reported that there are 18 residues of ACE2 that make direct contact with the SARS-CoV S protein (F. Li et al., 2005) (Table 2, columns marked *). For these 18 residues, there are six changes in rdACE2 compared with the cognate human protein: Q24L (Q in huACE2 and L in rdACE2 at residue 24), H34Y, D38E, M82T, N90D and the cognate human protein: Q24L (Q in huACE2 and L in rdACE2 at residue 24), H34Y, D38E, M82T, N90D and K353R, and four changes compared with pcACE2 (T31K, Q37E, V45L and K353R). Three regions within the S-ACE2 complex domain (W. Li et al., 2005a) differed significantly between rdACE2, huACE2 and pcACE2 (Table 2): the region of α-helix 1 (residues 30–41) varied at four residues from huACE2 and two from pcACE2; the loop initiating ACE2 α-helix 3 (residues 90–93) differed by two residues from huACE2 and three from pcACE2; and a loop and β5 (residues 353–357) had only one variation in rdACE2, and this variation (K353R in rdACE2) has never been found in any other species (although there is a histidine in the mouse and rat ACE2 proteins). This position was reported to be one of the most critical residues in ACE2 for binding to the SARS-CoV S protein (Li, 2008; F. Li et al., 2005; W. Li et al., 2005a).

**Generation of a HeLa cell line stably expressing the rdACE2 protein.** A HeLa cell line that stably expresses the rdACE2 protein was established as described in Methods. Rabbit polyclonal antibodies against huACE2, pcACE2 and rdACE2 were generated by using recombinant prokaryotic-expressed full-length ACE2 proteins. Western blot analysis showed that rdACE2 was expressed efficiently in HeLa cells and was

---

**Table 1.** Amino acid differences in the RBDs of S glycoproteins used in this study

<table>
<thead>
<tr>
<th>Virus</th>
<th>Residue at position</th>
<th>344</th>
<th>360</th>
<th>462</th>
<th>472</th>
<th>479</th>
<th>480</th>
<th>487</th>
</tr>
</thead>
<tbody>
<tr>
<td>Human SARS-CoV</td>
<td>KPF</td>
<td>LND</td>
<td>T</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>pcGD</td>
<td>RSP</td>
<td>PNG</td>
<td>S</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>pcES</td>
<td>RFP</td>
<td>RPS</td>
<td>G</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>rd03SZ</td>
<td>RSP</td>
<td>LKD</td>
<td>S</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>rd04GZ</td>
<td>RSP</td>
<td>RPS</td>
<td>G</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

---

**RESULTS**

**Generation of a HeLa cell line stably expressing the rdACE2 protein.** A HeLa cell line that stably expresses the rdACE2 protein was established as described in Methods. Rabbit polyclonal antibodies against huACE2, pcACE2 and rdACE2 were generated by using recombinant prokaryotic-expressed full-length ACE2 proteins. Western blot analysis showed that rdACE2 was expressed efficiently in HeLa cells and was
Fig. 1. Sequence analysis of rdACE2. (a) Multiple amino acid sequence alignment of ACE2 from different mammals. The GenBank accession numbers for the ACE2 proteins are as follows: raccoon dog, EU024940; dog, XM_537964; ferret, AB208708; raccoon, AB211998; masked palm civet, AY881174; bat, AB299376; human, AB193260.1; African green monkey, AY996037; cat, AB211997; mouse, AK141604; rat, AY881244. (b) A phylogenetic tree was constructed based on amino acid sequences of different ACE2 proteins using the neighbour-joining algorithm in the MEGA3.1 software package, with bootstrap values (%) determined by 500 replicates.
Table 2. Contacts between ACE2 and SARS-CoV RBD

<table>
<thead>
<tr>
<th>ACE2 protein</th>
<th>Raccoon dog</th>
<th>Dog</th>
<th>Raccoon</th>
<th>Palm civet</th>
<th>Bat</th>
<th>Human</th>
<th>SARS-CoV S</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACE2 residue</td>
<td>24* 27* 30</td>
<td>31*</td>
<td>32*33</td>
<td>34<em>41</em></td>
<td>42*</td>
<td>45*</td>
<td>79*</td>
</tr>
<tr>
<td>RBD residue</td>
<td>L T E K F N</td>
<td>Y</td>
<td>EA E E</td>
<td>LS Y Q L L</td>
<td>T Y D</td>
<td>S T V</td>
<td>Q N E N K G</td>
</tr>
<tr>
<td>Rat</td>
<td>90*</td>
<td>83*</td>
<td>79*</td>
<td>82*</td>
<td>82*</td>
<td>7*</td>
<td>P I Q N</td>
</tr>
<tr>
<td>Human</td>
<td>91*</td>
<td>92*</td>
<td>93*</td>
<td>325*</td>
<td>329*</td>
<td>330*</td>
<td>353*</td>
</tr>
</tbody>
</table>

These columns denote the 18 residues of ACE2 known to make direct contact with the SARS-CoV S protein.

Recognized by anti-rdACE2 antibody (Fig. 2). Moreover, cross-reactions with the three antibodies indicated that the cell lines expressed comparable amounts of the different proteins and that any of the antisera can be used effectively to detect the receptors from the three species (Fig. 2).

To detect the expression of ACE2 at the cell surface, FACS analysis was performed. The result is shown in Fig. 3. Cells stably expressing huACE2, pcACE2 or rdACE2 exhibited comparable positive-cell ratios (P > 0.05) when using FITC-conjugated rabbit anti-huACE2 antibody for detection, which were significantly higher than those for the control HeLa cells.

ACE2 proteins were assessed further by an enzyme-activity assay using an ACE2-specific peptide substrate, QFS. As shown in Fig. 4, membrane fractions prepared from the three cell lines displayed substantially higher protease activities toward QFS than the control HeLa cells (Fig. 4a). Furthermore, the protease activity was largely abolished in the presence of 0.1 mM EDTA, a known inhibitor of ACE2 proteases (Fig. 4b).

Analysis of S protein expression and pseudovirus packaging

The expression of different S proteins and their correct incorporation into pseudoviruses were monitored by Western blotting of purified virions using both S- and P24-specific mAbs. Pseudoviruses were purified by ultracentrifugation through a 20% sucrose cushion and subjected to SDS-PAGE for Western blotting with each antibody. The results showed that all genes encoding an S protein were expressed efficiently and incorporated into the respective pseudoviruses at comparable levels (Fig. 5).

Comparison of the entry efficiencies of different pseudoviruses into different ACE2-expressing cells

As shown in Fig. 6, when HIV/human-S pseudovirus was used to infect HeLa-huACE2, HeLa-pcACE2 and HeLa-rdACE2 cells, higher levels of luciferase activity (> 2 x 10^5 relative light units) were detected in the cell lysates of HeLa-rdACE2 than in HeLa-huACE2 and HeLa-pcACE2 cell lysates. If the entry efficiency of HIV/human-S pseudovirus into HeLa-rdACE2 cells was defined as 100%, then those of HIV/human-S pseudovirus into HeLa-huACE2 and HeLa-pcACE2 cells was 65.6 and 53.0%, respectively. Statistical analysis by SPSS software indicated that the entry efficiencies were significantly different from each other when HIV/human-S pseudovirus infected the three ACE2-expressing cell lines (P < 0.01). In contrast, when other animal-derived pseudoviruses were used to infect HeLa-rdACE2 cells, much lower luciferase activities were observed, especially when raccoon dog-derived pseudoviruses (HIV/rd03SZ-S and HIV/rd04GZ-S) were used. In the latter case, approximately 10^3 relative light units were detected, and the infection abilities were
<3% (1.5 and 2.5%, respectively) of that of HIV/human-S pseudovirus infected into HeLa-rdACE2 cells. Statistical analyses showed that, when HeLa-huACE2 and HeLa-rdACE2 cells were infected by HIV/rd03SZ-S and HIV/rd04GZ-S, the difference in entry efficiencies is not significant (P>0.05). However, it seems that HeLa-pcACE2 is relatively more acceptable to both HIV/rd03SZ-S and HIV/rd04GZ-S than HeLa-huACE2 and HeLa-rdACE2 (P<0.01). Meanwhile, we also observed that huACE2 is most sensitive to human-derived SARS-CoV, and pcACE2 is most sensitive to masked palm civet-derived SARS-CoV-like viruses, consistent with previous reports (W. Li et al., 2005a; Liu et al., 2007).

**DISCUSSION**

In this study, ACE2 from raccoon dog was cloned, sequenced and compared with ACE2s from human and palm civet for entry efficiency of SARS-CoV and SARS-CoV-like viruses.

Our results showed that rdACE2 could mediate human SARS-CoV entry more efficiently than huACE2 and pcACE2. Sequence analysis revealed that there are six changes in rdACE2 compared with huACE2, and four changes compared with pcACE2, within the 18 residues of ACE2 known to make direct contact with the SARS-CoV S protein (F. Li et al., 2005) (Table 2). These changes may contribute to the increased entry efficiency of human SARS-CoV. The most noticeable residue was 353, which was an arginine in rdACE2 that has never been found in any other species (although a histidine has been reported at this position in mouse and rat ACE2 proteins). This position was reported to be one of the most critical residues in ACE2 for binding the SARS-CoV S protein (F. Li et al., 2005; W. Li et al., 2005a; Liu, 2008). W. Li et al. (2005a) made a series of huACE2 variants in which one or a few solvent-exposed residues were altered to their rat ACE2 counterparts. Alteration of lysine 353 to a histidine residue, as present on the rat receptor, dramatically inhibited S protein-mediated entry. In contrast, introduction of human lysine 353 into rat ACE2 converted it to an efficient receptor for SARS-CoV. These data suggested that residue 353 in ACE2 plays a critical role in S-protein binding and subsequent cell entry. Structural studies of huACE2 complexed with the human SARS-CoV S-protein RBD suggested that the side chain of ACE2 Lys353 folds back and is embedded in a hydrophobic tunnel surrounded by Tyr484, Tyr491 and Thr487 of the RBD and Tyr41 of ACE2. At the opening of the tunnel is Asp38 of ACE2, which neutralizes the charge of Lys353 and stabilizes the interface. The stability and intensity of this complex appear to be critical for S–ACE2 interaction activity (F. Li et al., 2005; Liu, 2008). On rdACE2, Arg353 is present instead of Lys353 (which is present in the human and palm civet ACE2 proteins). Both arginine and lysine are positive-charged amino acids and arginine has a longer side chain, which may embed more deeply and more stably into the hydrophobic tunnel surrounded by residues 484, 491 and 487 of the RBD and residue 41 of ACE2. Interestingly, Glu38 occurs in rdACE2 instead of Asp38 in huACE2, both of which are negative-charged amino acids that can neutralize the positive charge of residue 353 and stabilize the interface. It is plausible that, in comparison to the human and palm civet ACE2 proteins, residue 353 of rdACE2 interacts more stably with surrounding residues and, with the interaction of Glu38, results in a more efficient SARS-CoV S-binding activity.

It is then interesting to know why, when pseudoviruses derived from palm civets and raccoon dogs were used, the binding efficiencies with rdACE2 were not higher than...
those of huACE2 and pcACE2. Li (2008) reported that the side chain of residue 38 of ACE2 by itself was not sufficient to form a strong and stable salt-bridge bond with residue 353, which appears to require support from the $\gamma$-methyl group of RBD Thr487. The $\gamma$-methyl group of the side chain of ACE2 residue 353 is important for placing the side chain of ACE2 residue 353 in position to form a salt bridge with ACE2 residue 38. Without this methyl group, residues at position 353 would not be able to form a strong and stable salt bridge with residue 38, leaving a free positive charge in a hydrophobic tunnel and destabilizing the interface (Li, 2008). However, RBD Thr487 in the human S protein is replaced by Ser487 in the palm civet and raccoon dog S proteins, and there is no $\gamma$-methyl group in Ser487. It has also been reported that Ser487 on RBD dramatically reduces the affinity for huACE2 by over 20-fold (W. Li et al., 2005a; Qu et al., 2005). This may explain why pseudoviruses derived from SARS-CoV-like viruses of palm civets and raccoon dogs had lower entry efficiencies into HeLa-rdACE2 cells than human SARS-CoV.

Another phenomenon that we observed in this study was that HeLa-pcACE2 cells are relatively more sensitive to pseudoviruses derived from SARS-CoV-like viruses of palm civets and raccoon dogs than HeLa-huACE2 and HeLa-rdACE2 cells. This is consistent with previous reports that pcACE2 was comparatively more susceptible to different S proteins than huACE2 (W. Li et al., 2005a; Li et al., 2006; Li, 2008). Meanwhile, we also observed that huACE2 is most sensitive to human-derived SARS-CoV, and palm civet-derived SARS-CoV-like viruses are most infectious to pcACE2, which has been reported previously (W. Li et al., 2005a; Liu et al., 2007).

In our study, the entry efficiency of pseudoviruses derived from raccoon dog S proteins was poor in the cell lines expressing huACE2, pcACE2 or rdACE2. This may reflect that the SARS-CoV-like viruses from raccoon dogs could not use these ACE2 proteins efficiently for cell entry. Amino acid sequence alignments of S-protein RBDs showed that rd04GZ has two single-nucleotide polymorphisms (SNPs) compared with pcGD or pcES: residues 462, 479 and 360.

**Fig. 4.** Determination of ACE2 activity. Protease activities from different ACE2-expressing cell-membrane fractions were determined by using the ACE2-specific substrate QFS (see Methods). Liberated fluorescence [in relative fluorescence units (RFU)] determined at 320–420 nm in the absence (a) and presence (b) of EDTA is shown. HeLa cells with no exogenous ACE2 gene and TBS buffer were used as negative controls. Error bars indicate SD.

**Fig. 5.** Detection of S protein incorporated into pseudoviruses. Western blotting of purified virions was performed with S-specific and P24-specific mAbs. Lanes: 1, HIV/human-S; 2, HIV/pcGD S; 3, HIV/pcES S; 4, HIV/rd03SZ S; 5, HIV/rd04GZ S; 6, HIV.

**Fig. 6.** Comparison of the entry efficiencies of different pseudoviruses into different ACE2-expressing cells. Five pseudoviruses derived from human, palm civet and raccoon dog are shown on the x-axis; detected luciferase activity/entry efficiency is shown on the y-axis. The entry efficiency of human-derived pseudovirus into HeLa-rdACE2 cells was regarded as 100 %. Empty, shaded and filled bars represent the entry efficiencies of different pseudoviruses into HeLa-huACE2, HeLa-pcACE2 and HeLa-rdACE2 cells, respectively.
means these three residues may have certain impacts on S–ACE2 interaction. Meanwhile, when the two raccoon dog-derived viruses were compared, there are four SNPs in the RBD: residues 462, 472, 479 and 480. Although their infectivities are very similar, it is possible that, when these four SNPs exist together, the influence on S–ACE2 interaction is limited. However, when another two mutations at residues 344 and 487 are added to the above four SNPs, virus entry efficiencies are inhibited dramatically, despite the hypothesis of Qu et al. (2005) and Li (2008) that the inhibition was mainly caused by mutations of residues 479 and 487. However, we need to mention that, apart from the RBD region, other parts of the S genes from the raccoon dog viruses also contain mutations that may have impacts on entry efficiency. Therefore, a more desirable conclusion can only be addressed when full-length S genes are used. It is also possible that another unknown molecule in the raccoon dog may serve as a receptor or co-receptor for raccoon dog SARS-CoV-like viruses, which will require further studies for verification.

Notably, amino acid sequence analysis indicated that rdACE2 has an identity of 99.3% to dog ACE2. Whether dogs are also susceptible to SARS-CoV infection is worthy of study. If so, dogs may be a good candidate for an animal model for SARS-CoV.

In summary, our results suggest that rdACE2 is a more efficient receptor for human SARS-CoV, but not for SARS-CoV-like viruses from palm civets and raccoon dogs, than the human and palm civet ACE2 proteins. The data indicate that raccoon dog may serve as a critical intermediate host for SARS-CoV and may play an important role in SARS outbreaks. The highly efficient interaction between SARS-CoV and rdACE2 may impose an important impact on the evolution of human SARS-CoV, whilst other host and environmental factors may also contribute to the emergence and spread of SARS-CoV. Therefore, further studies are required to understand completely the initiation of SARS outbreaks and animal reservoirs.

ACKNOWLEDGEMENTS

This work was supported by MOST projects (2003CB514118, 2005CB523004 and a special grant for ‘Animal Reservoir of SARS-CoV’), and by EU FP6 projects DISSECT (no. SP22-CT-2004-511060) and EPSARS (no. SP22-CT-2004-511603). We thank Dr Basil M. Arif (Wuhan Institute of Virology, CAS) for providing the pVPack and EPISARS (no. SP22-CT-2004-511603). We thank Dr Basil M. Arif (Wuhan Institute of Virology, CAS) for providing the pVPack and EPISARS (no. SP22-CT-2004-511603). We thank Dr Basil M. Arif (Wuhan Institute of Virology, CAS) for providing the pVPack and EPISARS (no. SP22-CT-2004-511603). We thank Dr Basil M. Arif (Wuhan Institute of Virology, CAS) for providing the pVPack and EPISARS (no. SP22-CT-2004-511603). We thank Dr Basil M. Arif (Wuhan Institute of Virology, CAS) for providing the pVPack and EPISARS (no. SP22-CT-2004-511603). We thank Dr Basil M. Arif (Wuhan Institute of Virology, CAS) for providing the pVPack and EPISARS (no. SP22-CT-2004-511603). We thank Dr Basil M. Arif (Wuhan Institute of Virology, CAS) for providing the pVPack and EPISARS (no. SP22-CT-2004-511603). We thank Dr Basil M. Arif (Wuhan Institute of Virology, CAS) for providing the pVPack and EPISARS (no. SP22-CT-2004-511603). We thank Dr Basil M. Arif (Wuhan Institute of Virology, CAS) for providing the pVPack and EPISARS (no. SP22-CT-2004-511603).

REFERENCES


Leydig cells of the testis.

Endocrinology 145, 4703–4711.


